Nasdaq's Bitcoin Options Approval Is Back Under Review in an SEC-CFTC Turf Fight

Here’s the short version: Nasdaq’s plan to list cash-settled Bitcoin index options looked greenlit in May, then a filing from CME pulled the handbrake. If you’re trying to figure out what’s actually approved, who’s in charge, and whether anything trades soon, you’re in the right place.

We’ll unpack what the SEC approved, why CME is challenging it, how SEC and CFTC lines get drawn, and what this means for timing, risk, and positioning. No fluff. Just the moving parts you need to watch now.

Nasdaq PHLX’s Bitcoin Index Options received an SEC approval order in May, but trading isn’t happening yet. CME has asked the SEC to review and vacate that approval, arguing the contracts belong under the CFTC’s jurisdiction, not the SEC’s. The SEC page was updated on July 8 to surface CME’s petition, and the original order already flagged that trading would require CFTC exemptive relief because bitcoin is treated as a commodity. Translation: the launch is on ice while the jurisdiction question gets sorted.

• SEC’s Phlx approval order posted May 22, 2026, with a CFTC relief prerequisite (SEC).
• On July 8, 2026, the SEC’s page added a link to CME’s Petition for Review (SEC SR‑Phlx‑2025‑50).
• CME’s June 18 petition asks the Commission to vacate the approval, calling the options commodity option swaps under CFTC control (CME Group petition).
• No trading until CFTC exemptive relief is granted, per the SEC’s own order (SEC).

What did the SEC approve, and what just changed?

In late May, the SEC’s Division of Trading and Markets approved Nasdaq PHLX’s proposal to list cash-settled, European-style options tied to the Nasdaq Bitcoin Index, with the proposed ticker QBTC. That’s in the formal order dated May 22, 2026. Importantly, the order didn’t open the gates to trading immediately. It explicitly noted that the contracts couldn’t start until the CFTC granted the needed exemptive relief because bitcoin is treated as a commodity under the Commodity Exchange Act. You can see that condition spelled out on the SEC’s rulemaking page for SR‑Phlx‑2025‑50 (SEC).

Then came a curveball. On July 8, 2026, the SEC updated that same page and added a link titled “CME Petition to Review Approval of Nasdaq Bitcoin Options.” That link points to CME Group’s formal Petition for Review, which the SEC is now hosting (SEC-hosted petition PDF). The petition itself is dated June 18, 2026, but the public breadcrumb on the SEC site went live July 8 (SEC SR‑Phlx‑2025‑50).

Bottom line: the approval exists, but it’s under review. And there was already a CFTC-related condition that would’ve kept the launch from going live right away anyway. The petition just raises the stakes.

Why is CME challenging this?

CME’s argument is straightforward: these are commodity options, not securities options, because they’re tied to bitcoin, which the CFTC treats as a commodity. Under that view, the CFTC has exclusive jurisdiction. CME is effectively saying the SEC can’t approve these as securities options listed on an SEC-regulated options exchange unless the CFTC acts first or explicitly carves out the right relief. That’s spelled out in the petition filed June 18, 2026 (CME Group petition).

There’s a competitive angle too. bitcoin futures and options under the CFTC’s umbrella. If SEC-regulated options exchanges can list cash-settled bitcoin index options under the securities framework, we’re talking about a parallel venue and a different regulatory playbook. That could shift liquidity, margining, and market structure. CME has every incentive to make sure the jurisdiction lines are clean before a rival product hits screens.

It’s worth noting the SEC’s own approval already acknowledged the CFTC’s role by requiring exemptive relief before trading could start. So even without the petition, the baton would’ve needed to pass to the CFTC for that step (SEC).

Who regulates what in plain English?

Here’s the simplest way to slice it. The SEC oversees securities. Stocks, ETFs, standardized listed options on securities, and exchanges like Nasdaq and PHLX. The CFTC oversees commodities and derivatives on them. That includes bitcoin and ether when we’re talking about futures and options on futures, as well as swaps, and exchanges like CME.

The tricky bit is where a cash-settled index option that references bitcoin fits. If it’s treated as a securities option because of how it’s structured, lists, clears, and is supervised, SEC has a claim. If it functions like a commodity option or a swap referencing a commodity index, then it looks more like a CFTC product. CME’s petition says it’s the latter, in clear terms, and asks the SEC to vacate the approval so the CFTC’s framework controls (CME Group petition).

One more nuance: the SEC’s approval wasn’t a green light to trade. It folded in the need for CFTC exemptive relief first. That’s a strong tell that even within the SEC, staff recognized the commodity dimension and the need to square the circle with the CFTC before anyone puts on a spread (SEC).

What does this mean for traders right now?

Short answer: you can’t trade these Nasdaq Bitcoin Index Options today. The rule text might be approved, but the products are on hold both because of the CFTC relief requirement and because the SEC is now staring at a formal petition to review and potentially vacate the approval.

If you’re hedging or speculating on bitcoin vol in the meantime, your current menu hasn’t changed. There are CFTC-regulated futures and options on CME. There are listed options on certain bitcoin ETFs under the SEC regime. And there’s the offshore venue universe, which carries its own set of risks and legal baggage. If these PHLX options eventually clear the gauntlet, they’d add a securities-market alternative for directional and spread strategies that reference an index level rather than a fund share price or a futures curve.

From a risk standpoint, treat this as a process story. Timelines can get long when two agencies and a major exchange are involved. Any launch window talk you hear is speculation until the CFTC piece is nailed down and the SEC decides what to do with CME’s petition.

How do these options compare to current alternatives?

If and when Nasdaq’s contracts go live, they’ll sit alongside CME’s crypto derivatives and options on spot bitcoin ETFs. Same underlying theme, different plumbing. Here’s a quick view of the main differences traders care about.

Why this matters: index options could let you target bitcoin level risk without the ETF wrapper and without rolling futures, though the cash-settlement mechanics and index calculation rules will matter a lot in practice. But none of it matters until the jurisdiction fight is settled and the CFTC signs off on relief the SEC already said is needed (SEC).

What risks should you watch during a turf fight?

When two regulators have skin in the game, the biggest risk is delay. That bleeds into liquidity risk if order books debut thin after a long wait. It also creates documentation risk: rule text, margin schedules, and clearing arrangements can change between initial approval and the eventual live date.

• Regulatory slippage: watch for new conditions layered onto any final approval or relief.
• Margin methodology drift: parameters can tighten if supervisors get nervous about vol regimes.
• Operational toggles: listing dates can move late in the game if an agency asks for tweaks.
• Basis and reference risk: index calculation and halt rules could deviate from what you expect.
• Headline whipsaw: product-specific headlines can spill over into related markets for a day or two.

Pro tip: treat “approval” headlines as conditional until you see a final effective date, product specs on the exchange website, and clearing readiness. Here, the SEC’s own order tied activation to CFTC exemptive relief, and now there’s a live petition asking the Commission to vacate that approval (CME Group petition; SEC page).

None of this is financial advice. It’s just the real-world mess of launching a first-of-its-kind instrument across two supervisory regimes.

How might the process play out from here?

Procedurally, a Petition for Review asks the Commission itself to re-examine a staff approval. The Commission can affirm, modify, or vacate. Along the way, the SEC could request additional comment, cue up briefings, or set a schedule. That can take weeks to months, depending on the complexity and the docket.

In parallel, the CFTC side matters because the SEC’s order already made CFTC exemptive relief a condition of trading. That means even if the SEC lets the approval stand, nothing lists until the CFTC acts. If the SEC vacates, Nasdaq PHLX may need to rework the product or route the whole thing through a different framework that satisfies the CFTC.

Realistically, traders should assume a multi-step path: SEC decision on the petition, CFTC decision on relief, exchange operational readiness, and then a go-live notice. Each step can slip. If you plan to use these options on day one, build in flexibility.

How do I evaluate whether these options are worth it if they launch?

You’ll want to compare them to your current toolkit. If you hedge spot or ETFs, index options could give cleaner exposure to the level of bitcoin without ETF-specific tracking or futures roll dynamics. If you’re already comfortable in futures options, you may prefer the depth and familiarity of CME’s market. The answer will be personal to your mandate and margin setup.

• Cost stack: commissions, fees, and implied funding via margin.
• Greeks behavior: settlement to index vs to ETF NAV or futures can shift delta and gamma feel around expiry.
• Liquidity continuity: opening days can be patchy. Size accordingly.
• Clearing access: confirm your clearer is ready to process the specific series and has risk flags set.
• Spec language: read the rulebook for halt and disruption procedures tied to the index inputs.

Given the regulatory overhang, plan for the possibility that specs evolve before launch. Small wording changes can have big P&L consequences on settlement day.

Common Mistakes

1. Assuming an approval order equals a launch date. It doesn’t here. The SEC order conditions trading on CFTC exemptive relief, and the petition adds another review layer. Avoid planning risk around headlines alone (SEC).
2. Ignoring jurisdictional nuance in docs. If position limits, margin, or halt rules change during review, your playbook can break. Track updates to the SRO filing and any Commission notices.
3. Sizing day-one trades like mature markets. Early books can be thin. Use limit orders, test spreads, and stage entries.
4. Conflating index settlement with ETF settlement. The reference, timing, and fallbacks may differ. Read the fine print before structuring expiry-sensitive trades.
5. Overlooking clearing readiness. Some FCMs and brokers gate new products. Get pre-approval well before any launch window.

Frequently Asked Questions

Are these Nasdaq Bitcoin Index Options live right now?

No. The SEC’s approval doesn’t activate trading. The order requires CFTC exemptive relief first, and the approval itself is under a Petition for Review posted on the SEC’s site on July 8, 2026 (SEC page).

What exactly did CME ask the SEC to do?

CME asked the Commission to review and vacate the Division’s May 22, 2026 approval order, arguing the contracts are commodity option swaps that fall under the CFTC’s exclusive jurisdiction (CME Group petition).

Could the SEC and CFTC both have a role here?

Yes. The SEC already recognized a CFTC role by conditioning trading on CFTC exemptive relief. That suggests coordination is required even if the SEC approval stands (SEC order).

How is this different from options on spot bitcoin ETFs?

ETF options are securities options on fund shares and squarely under the SEC. Nasdaq’s proposal targets an index level tied to bitcoin. CME’s view is that makes it a commodity option subject to the CFTC, not a securities option, which is the heart of the dispute.

What’s a realistic timeline for resolution?

There isn’t a public deadline. Commission reviews can take weeks to months. Add the CFTC relief step and you’re looking at a multi-stage process rather than a single date to circle.

Could this end with a different product design?

Possibly. If the SEC vacates or the CFTC demands changes for relief, specifications might be revised. Seemingly small edits to settlement, halts, or index inputs can be material for strategy.

What should I monitor next?

Watch the SEC’s SR‑Phlx‑2025‑50 page for any Commission action on the petition and the CFTC’s public actions for exemptive relief. Those two items will decide when, and if, listing day arrives (SEC page).

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Share With Others